Effect of denosumab treatment on bone mineral density and bone turnover markers in osteoporotic patients: real-life experience 2-year follow-up

ConclusionIn our group of patients under denosumab treatment, 53% of persistence was found at 24  months and associated with improvement in BMD levels without any significant side effects except one case with urticarial reaction. Denosumab leads to improvements in BMD levels and is a well-tolerated agent in a real-life setting comparable to results of randomized controlled studies in patients with different comorbidities.
Source: Archives of Orthopaedic and Trauma Surgery - Category: Orthopaedics Source Type: research